Medical Transcription Billing (MTBC) Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of Medical Transcription Billing (NASDAQ:MTBC) from a buy rating to a hold rating in a report published on Saturday.

According to Zacks, “Medical Transcription Billing, Corp. is a healthcare information technology company. It engages in providing integrated suite of proprietary web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company offers revenue cycle, practice management services, patient scheduling, automated appointment reminders, e-prescribing, lab connectivity, and real-time insurance eligibility verification. Transcription Billing, Corp. is headquartered in Somerset, New Jersey. “

Other research analysts have also issued reports about the company. ValuEngine lowered Medical Transcription Billing from a hold rating to a sell rating in a research report on Monday, December 4th. Chardan Capital increased their price objective on Medical Transcription Billing from $2.25 to $2.75 and gave the company a buy rating in a research report on Tuesday, November 14th.

Medical Transcription Billing (NASDAQ MTBC) opened at $3.16 on Friday. The company has a market capitalization of $36.44, a price-to-earnings ratio of -3.04 and a beta of 1.79. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.15 and a quick ratio of 1.15. Medical Transcription Billing has a 12-month low of $0.29 and a 12-month high of $5.44.

In other news, CEO Mahmud Ul Haq acquired 30,000 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were purchased at an average cost of $2.93 per share, for a total transaction of $87,900.00. Following the transaction, the chief executive officer now owns 5,017,070 shares of the company’s stock, valued at $14,700,015.10. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, President Stephen Andrew Snyder sold 50,000 shares of the stock in a transaction on Monday, November 6th. The shares were sold at an average price of $3.18, for a total value of $159,000.00. Following the completion of the transaction, the president now owns 106,000 shares in the company, valued at $337,080. The disclosure for this sale can be found here. 53.70% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: “Medical Transcription Billing (MTBC) Lowered to Hold at Zacks Investment Research” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.themarketsdaily.com/2018/01/10/medical-transcription-billing-mtbc-lowered-to-hold-at-zacks-investment-research.html.

About Medical Transcription Billing

Medical Transcription Billing, Corp. is a healthcare information technology company that provides an integrated suite of Web-based solutions, together with related business services, to healthcare providers practicing in ambulatory care settings. The Company’s offering, PracticePro, allows healthcare practices with the core software and business services on Software-as-a-Service (SaaS) platform.

Get a free copy of the Zacks research report on Medical Transcription Billing (MTBC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Medical Transcription Billing Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medical Transcription Billing and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply